Larimar Therapeutics Inc (LRMR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $313.73M
Last updated: Nov 17, 2026 at 11:06 AM ET
Larimar Therapeutics Inc (LRMR) Stock Forecast
Analysts expect Larimar Therapeutics (LRMR) to earn -$1.37 per share in the fiscal year ending Dec 31, 2026. Of 11 analysts, 11 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 6 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 1.82, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 18.2% |
| Buy | 9 | 81.8% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$1.37
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.06
- EPS consensus, revenue $41.74M
- Next report
- Mar 17, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.37 | -$1.52 to -$1.14 | 8 | N/A | N/A | 11 |
| Dec 31, 2027 | -$1.06 | -$1.49 to -$0.29 | 8 | $41.74M | $4.63M to $164.50M | 11 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.38 | -$0.44 to -$0.33 | 13 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 11 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 6 | 0 |
| Fiscal year ending Dec 31, 2027 | 5 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.35.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.37 | -$1.35 | -$1.35 | -$1.35 | -$1.35 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.06 | -$1.06 | -$1.06 | -$1.06 | -$1.06 | N/A |
Frequently Asked Questions About LRMR
What is the LRMR stock forecast?
Consensus analyst estimates put Larimar Therapeutics's EPS at -$1.37 for the fiscal year ending Dec 31, 2026. The consensus rating from 11 analysts is Buy.
How do analysts rate LRMR stock?
Of 11 analysts covering Larimar Therapeutics, 2 rate it Strong Buy, 9 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from LRMR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.37, with estimates from -$1.52 to -$1.14 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.06, with estimates from -$1.49 to -$0.29 from 8 analysts.
What revenue do analysts expect from Larimar Therapeutics next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $41.74M, with estimates from $4.63M to $164.50M.
How many analysts cover LRMR?
11 analysts rate Larimar Therapeutics stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
LRMR pages: Overview, Earnings, Forecast, Financials, Competitors